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Summary 
The RMA-S cell line was derived from the Raucher virus-induced murine cell line RBb5 by 
ethylmethane sulfonate mutagenesis and anti-H-2 antibody plus complement selection (Ljunggren, 
H.-G., and K. Karre. 1985.J. Exp. Med. 162:1745). RMA-S is defective in the ability to present 
endogenously synthesized antigens to class I major histocompatibility complex (MHC)-restricted 
cytotoxic T lymphocytes (CTL) (Townsend, A., C. Ohlen, J. Bastin, H.-G. Ljunggren, L. Foster, 
and K. Karre. 1989. Nature fLond.]. 340:443;  Ohlen, C., J. Bastin, H.-G. Ljunggren, L. Foster, 
E. Wolpert, G. Klein, A. R. M. Townsend, and K. Karre. 1990.J. Immunol. 145:52). This defect 
has been attributed to the inability of RMA-S to deliver antigenic peptides derived from antigens 
in the cytosol into the endoplasmic reticulum (ER), where they can associate with class I MHC 
molecules (Townsend, A., C. Ohlen, J. Bastin, H.-G. Ljunggren, L. Foster, and K. Karre. 1989. 
Nature ILond.]. 340:443).  We show that RMA-S can present at least one endogenous antigen, 
vesicular stomatitis virus nucleoprotein (VSV-N), to dass I MHC-restricted CTL. RMA-S presents 
VSV-N to CTL both when infected with VSV or transfected with the VSV nucleoprotein gene. 
The natural antigenic VSV nucleoprotein peptides purified from either RMA or RMA-S are 
indistinguishable when analyzed by high performance liquid chromatography. We also show 
that the genetic defect responsible for the RMA-S phenotype maps to the murine chromosome 
17. This chromosome encodes the murine class I MHC genes as well as two genes, HAM-1 
and -2, with homology to the adenosine triphosphate-dependent transporter superfamily (Monaco, 
J. J., S. Cho, and M. Attaya.  1990. Science [Wash. DC]. 250:1723).  These results suggest that 
the system that delivers antigenic peptides from the cytosol to the ER in RMA-S may still be 
present and retain partial function. 
C 
lass I MHC molecules present short peptides derived 
from endogenous proteins to antigen-specific, class I-re- 
stricted T cells (1-4).  These peptides are thought to be de- 
rived by an unknown mechanism in the cytosol and deliv- 
ered by a peptide transport system from the cytosol into the 
lumen of the endoplasmic reticulum (ER), 1 where they can 
associate with class I MHC molecules (5). Evidence for the 
existence of a peptide transport system comes from analysis 
of several cell lines defective in the ability to present endoge- 
nous antigens to class I-restricted CTL. These cell lines in- 
clude the human mutant LCL 721.174 and the murine mu- 
tant RMA-S. These cell lines were derived in a similar manner 
by either "y irradiation (LCL 721.174) or ethylmethane sul- 
fonate (EMS) mutagenesis (RMA-S) followed by several  rounds 
of selection with anti-MHC antibody plus complement (6, 
1 Abbreviations used in this paper: B2m, /32-microglobulin; EMS, ethyl- 
methane sulfonate; ER, endoplasmic reticulum; HALl, hemagglutinating 
units; MOI, multiplicity of infection; NP, nucleoprotein. 
7). They also display a phenotype that has several common 
features. First, they retain the majority of their class I MHC 
molecules in the ER in an incompletely assembled state (5, 
8, 9). Treatment of these cell lines with IFN-~/does not re- 
sult in increased cell surface expression of class I MHC mole- 
cules (6, 10). However, addition of large quantities of exoge- 
nous antigenic peptides to these cell lines induces increased 
cell surface expression of stable class I MHC molecules (5, 
9, 11). A second common phenotypic feature of these mu- 
tants is that they are able to present exogenous antigenic pep- 
tides, but not endogenous antigens, to class I-restricted CTL, 
suggesting that their class I MHC molecules are fully func- 
tional (5, 9, 12, 13). Last, the genetic defect in these cell lines 
is either recessive or null in fusions between the mutants and 
normal cell lines and is not due to defects either in the class 
I heavy chains or ~2-microglobulin (B2m) encoded by the 
mutant cell lines (10, 14). These observations have led to the 
hypothesis that these cell lines are defective in the ability to 
transport antigenic peptides into the lumen of the ER (5, 
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and selection experiments performed with the LCL 721.174 
mutant. These experiments mapped the genetic location of 
the defect in LCL 721.174 to the human chromosome 6 (10). 
LCL 721.174 has a large deletion in the class II region of the 
MHC on chromosome 6 (15). Included within this deletion 
are genes with homology to members of the ATP-dependent 
transporter superfamily that may encode all or part of a pep- 
tide transport system (16, 17). Evidence that one of these 
genes (Y3) may encode at least part of a peptide transporter 
was provided by experiments showing that transfection of 
LCL 721.134 cells that lack Y3 expression with the Y3 cDNA 
restored high levels of HLA class I expression at the cell sur- 
face (18). The mutant LCL 721.134 was derived from the 
same series of mutagenesis and antibody plus complement 
selection experiments as LCL 721.174 (7). Transfection with 
the Y3 cDNA did not restore high levels of cell surface class 
I expression  by the LCL 721.174 mutant cell line (18). The 
genetic defect responsible for the RMA-S phenotype is less 
well characterized than the defect in LCL 721.174. Like LCL 
721.174, RMA-S has been shown to be unable to present several 
endogenous antigens to CTL (5,  12). We show here that 
RMA-S differs from LCL 721.174 in being capable  of pre- 
senting at least one endogenous antigen, VSV-N, to class I-re- 
stricted CTL. We, and others, have previously reported that 
LCL 721.174 is unable to present any of several endogenous 
antigens, including VSV-N, to class I-restricted CTL (9, 13). 
We also provide evidence that the genetic defect responsible 
for the RMA-S phenotype maps to the murine chromosome 
17, which encodes the murine MHC as well as the putative 
peptide transporter genes HAM-1 and -2 (19). It has been 
shown that RMA-S expresses mRNA for, and has therefore 
not deleted, the MHC-linked, putative peptide transporter 
genes HAM-1 and -2 (20). Based on these data, we speculate 
that the system that delivers antigenic peptides from the cytosol 
to the ER in RMA-S may still be present and retain partial 
function. 
Materials  and Methods 
Mice.  Young adult female C57B1/6, C57B1/10, AKR/J, and 
B10.BR mice were obtained from The Jackson Laboratory (Bar 
Harbor, ME). 
Cell  Lines.  The  C57B1/6 (H-2  b,  B2M  b,  Thy-l.2)-derived, 
EMS-mutagenized cell line RMA and the mutagenized and anti- 
body plus complement-selected  cell  line RMA-S were obtained from 
Dr. Linda Sherman (Research Institute of Scripps Clinic, La  Jolla, 
CA) with the permission of Dr. Klaus Karre (6). The human cell 
lines, T2K  b and Jurkat/K  b,  transfected with the murine class I 
H-2K  b gene were obtained as described previously (13). BW Lyt- 
2.4, an AKR/J (H-2  k,/32m  ......  b, Thy-l.1)-derived cell line trans- 
fected with the routine Lyt-2 gene, was obtained from Dr. Phillipa 
Marrack (National Jewish Center for Immunology and Respira- 
tory Medicine, Denver, CO) (21). 
Cytotoxic  T  Cells.  The VSV-N-specific CTL line was derived 
from spleen cells from C57B1/6 mice primed intraperitoneaUy  with 
106 PFU of VSV (Indiana) 7 d before restimulation in vitro as de- 
scribed previously (13). The chicken OVA-specific CTL clone B3 
was derived from spleen cells from C57B1/6 mice primed in vivo 
with the OVAa~-27~ peptide and restimulated and cloned in vitro 
as described previously (22). The influenza nucleoprotein (NP)- 
specific CTL line was derived from C57B1/6 mice primed in- 
traperitoneally  with  100  hemagglutinating  units  (HALl) of 
A/PK/8/34 influenza  virus 7 d before  restimuIation  in vitro. Spleen 
cells (3  x  107) from A/PR/8/34 virus primed mice were stimu- 
lated  twice  in  vitro  with  3  x  107  irradiated  (3,000 rad) 
A/PK/8/34 virus-infected  (1,000 HALT  per spleen) syngeneic  spleen 
cells in RP10 medium (RPMI 1640 containing 10% FCS and 50 
/~M 2-ME) in upright 25-cm  2 flasks at  37~  in  7%  COs/air. 
Thereafter, 0.5-1.0  ￿  10  s CTL were restimulated with 5  x  106 
irradiated (3,000 rad) syngeneic spleen cells coated with synthetic 
NPzes-3s0 peptide (200 #g/10  s cells) per well of a 24-well plate in 
RP10 medium containing 50 mM c~-methyl mannoside and 5% 
supernatant from Con A-stimulated rat spleen cells at 37~  The 
alloreactive C57B1/6 (H-2  b) anti-B10.BR (H-2  k) CTL line was de- 
rived by primary in vitro stimulation of 3  x  107 C57B1/6 spleno- 
cytes with 3  x  107 irradiated (3,000 rad) B10.BR spleen cells in 
10 ml KP10 medium in upright 25-cm  2 flasks for 7 d at 37~ 
The responding cells (5  x  10  ~) were restimulated every 7 d with 
3  x  107 irradiated (3,000 rad) B10.BR spleen cells in 10 ml RP10 
medium containing 50 mM c~-methyl  mannoside and 5% super- 
natant from Con A-stimulated rat spleen cells in upright 25-cm  2 
flasks at 37~ 
Chromium Release CTL Assays.  Target  cells (1@) were infected 
with 200 HALT  of  either A/PR/8/34 or recombinant  X31 influenza 
virus in RPMI 1640 with 200/~Ci sodium [SlCr]chromate  for I h 
at 37~  OVA was introduced into the cytoplasm of 106 sodium 
[SlCr]chromate-labeled target cells by the method of the osmotic 
lysis of pinosomes with 100/zl of hypertonic medium containing 
10 mg/ml OVA as previously  described (23). Target cells (10  ~) were 
infected with VSV(Indiana) at a multiplicity of infection (MOI) 
of 40 in HBSS containing 200 #Ci of sodium [SlCr]chromate for 
1 h at 37~  After washing with PBS, virus-infected  or OVA-loaded 
target cells (104) were incubated with serial dilutions of effector 
CTL in wells of a round-bottomed 96-well plate with or without 
added NPats-3s0 (10/~M), OVA242-276 (10/~M), or Ns3~3 (10 nM) 
synthetic peptides in a total volume of 200/~1 of RP10 medium. 
After 3 h of incubation at 37~  100 #1 of the supernatant was 
collected, and the amount of released chromium determined using 
a gamma counter (Beckman Instruments,  Inc., Palo Alto, CA). 
Percent specific  lysis =  100x  [(release by CTL -  spontaneous re- 
lease)/(release by detergent -  spontaneous release)]. Spontaneous 
release of chromium in the absence of CTL was <20%  of deter- 
gent release in all experiments. 
Transfection of RMA and RMA-S.  The pSV2neo-RSV-N vector 
for expression of VSV(Indiana) NP in mammalian cells was ob- 
tained from Dr. Leo LeFrancois (Upjohn, Kalamazoo, MI) (24). 
RMA (5  x  107) and RMA-S (2  x  107) cells were transfected  with 
10 #g of circular plasmid in 1 ml PBS by electroporation at 375 
V, 50 ms, and 1,400/zF using an X-Cell electroporater (Promega 
Biotec, Madison, WI).  Surviving cells were cultured in RP10 
medium at 37~  overnight. The cells were then plated at 10  4 per 
well in flat-bottomed 96-weU plates in RP10 medium containing 
600  /~g/ml G418 (effective concentration) (Gibco Laboratories, 
Grand Island, NY). After 14-21 d, G418-resistant colonies were 
transferred to individual wells of a 24-well plate containing RP10 
with 600 #g/ml G418. Clones testing positive for recognition by 
VSV-N-specific CTL, including RMA/N.4 and RMA-S/N.4, were 
maintained in culture in RP10 medium containing  600 #g/ml G418. 
FACS |  Analysis of Cell Lines.  Cells  (0.3-1.0  x  106) were first 
incubated with either 100/zl of  antibody-containing ascites diluted 
to the appropriate concentration in PBS/1% BSA (wt/vol),  200 
720  RMA-S  Can Present an Endogenous Antigen #1 of hybridoma supernatants, or 100 #1 PBS/1% BSA alone for 
30 min on ice. The cells were washed once with ice-cold PBS and 
incubated with 100 #1 of  either FITC-hbeled antibody against mouse 
immunoglobulin  Fc (Cappel Laboratories, Mulvern, PA) diluted 
1:50 in PBS/1% BSA. FITC-labeled 30H12 antibody (Boehringer 
Mannhdm Biochemicals, Indianapolis, IN) diluted 1:20 in PBS/I% 
BSA, or PBS/1% BSA alone for 30 min on ice. The ceils were then 
washed once with ice-cold PBS and resuspended in PBS containing 
1% formaldehyde (vol/vol). Analysis of 10,000 gated events per 
sample of stained cells was performed on a PACScan  |  flow cytom- 
eter (Becton Dickinson  & Co., Mountain View, CA). 
Purification of Naturally Processed VSV-N Peptides.  Cell lysates 
of RMA (5  x  10s), RMA-S (5  x  los), RMA/N.4 (5  x  los), 
RMA-S/N.4  (6  x  los),  and both RMA  and RMA-S infected 
with VSV (108 each; MOI  =  40) were prepared in 0.1%  TFA 
(vol/vol) as previously described (25). The lysates were lyophilized, 
resuspended in 0.1% TFA, and passed over a Sephadex  G-25 column 
and eluted with 0.1% TFA. The included column volume was col- 
lected, lyophilized, resuspended in 1.0 ml of 0.1% TFA, and chro- 
matographed by reverse-phase  HPLC on a C18 column (Delta Pak; 
Waters Associates, Milford, MA) using a 0-60% acetonitrile gra- 
dient. 1-ml fractions were collected, lyophilized, and resuspended 
in 250 #1 RPMI 1640. 50 #1 of RP10 medium containing 104 so- 
dium  [S~Cr]chromate-labeled RMA-S target ceils that had been 
previously cultured at 31~  overnight was added to 50 #1 of each 
fraction in wells of round-bottomed 96-well plates, and the plates 
were incubated at 31~  for 1 h. Anti-VSV CTL were then added 
to the wells, bringing the total volume of RP10 medium per well 
to 200/~1, and the plates were incubated at 37~  for 4 h. 
Fusion of RMA-S with BW Lyt-2.4 and Subsequent CTL Selec- 
tion.  RMA-S  (G418  s,  HAT~; 5  x  1@ cells) and  BW Lyt-2.4 
(G418  r, HAT~; 5  x  106 cells) were combined in a 15-ml conical 
tube, washed once with warm (37~  RPMI 1640, pelleted, and 
all RPMI was removed  from the cells. 0.5 ml of  warm 50% (vol/vol) 
polyethylene glycol 1000 in RPMI 1640 was slowly added to the 
cell pellet over a 2-min period.  The cells were then pelleted for 
2 min and incubated for an additional 2 min at room temperature. 
Warm KPMI 1640 (10 ml) was then slowly added to the cells over 
a 2-min period. The cells were pelleted and gently resuspended in 
warm RP10 medium and cultured at 37~  overnight. The following 
day, the cells were plated at 104 per well in flat-bottomed 96-weU 
plates in RP10 medium containing 600 #g/ml G418 (effective  con- 
centration)  and  lx  HAT  (100 #M  hypoxanthine,  0.4  #M 
aminopterin, and 16 #M thymidine; Sigma Chemical Co., St. Louis, 
MO). After '~14 d of incubation at 37~  viable clones were trans- 
ferred to individual wells of 24-well  plates containing RP10 medium 
with 600 #g/ml G418 and 1￿  HT (100 #M hypoxanthine, and 
16 #M thymidine; Sigma Chemical Co.). 40 individual clones were 
screened by FACS  |  analysis for expression of H-2K  b and H-2K  ~ 
class I MHC molecules and clone RxB.6 chosen for further anal- 
ysis. Selection of RxB.6 was performed by mixing 107 Rx.B.6 cells 
with C57BL/6 anti-B10.BK CTL at E/T ratios of either 0.3:1 (Sel 
3 and 5) or 1:1 (Sel 4) in 20 ml of RP10 medium containing  50 
mM co-methyl  mannoside and 5% supematant from Con A-stimu- 
lated rat spleen cells in upright 25-cm  2 flasks. After incubation at 
37~  for 24 h, the cells from each culture were pelleted, resuspended 
in 5 ml RPl0 medium, and cultured in a single well of a six-well 
plate. Each culture was harvested after 7 d at 37~  Dead cells and 
cell debris were removed with Ficoll and the remaining viable cells 
expanded and maintained in culture in KP10 medium  at 37~ 
Southern Blot Analysis.  Genomic DNA was prepared by over- 
night incubation at 370C of 107 tumor ceils or los spleen cells in 
0.5 ml Lysis Buffer (1 M Tris, 5 M NaC1, 0.5 M EDTA, 10% SDS 
[wt/vol]) containing 100 #g/ml proteinase  K and 20 #g/ml RNAse. 
The next day, 125 #1 of a saturated NaC1 solution was added to 
each lysate. The lysates were vortexed vigorously and then spun 
in a microfuge for 15 min. The supematants were extracted with 
phenol and the DNA was precipitated by the addition of 1 ml of 
ethanol. 2 #g of HindlII-digested  DNA from each cell line was 
subjected to electrophoresis on a 0.8% agarose gel in TBE buffer 
(45 mM Tris-Borate, 1 mM EDTA) at 40 V overnight. The DNAs 
were then blotted onto a nylon membrane (Nytran; Schleicher & 
Schuell, Inc., Keene, NH), crosslinked to the membrane with UV 
irradiation (120  millijoules)  using a Stratalinker (Stratagene,  La  Jolla, 
CA), and the blot probed with a purified 3-kb EcoRI-HindlII frag- 
ment  from the  genomic  5'  promoter of H-2K  b in  a 0.25  M 
NaHzPO4,  0.25  M  NazHPO4, 2%  SDS  (wt/vol),  1%  BSA 
(wt/vol) solution at 65~  overnight.  The blot was then washed 
with a 0.Sx  SSC/0.1% SDS (wt/vol) solution at 65~  for 1.5 h 
and autoradiographed. 
Results 
Presentation of Endogenous Antigens by RMA and RMA-S. 
The RMA-S cell line has been reported to be unable to present 
several endogenous antigens, including tumor-specific antigens, 
minor histocompatibility antigens, and influenza NP, to class 
I-restricted CTL (5, 12). Of these antigens, only the influenza 
NP epitope has been identified and its class I MHC restric- 
tion element defined (26). To further characterize the RMA-S 
defect, we compared the presentation of influenza NP with 
that  of two well-characterized H-2Kb-restricted antigens, 
OVA  and VSV-N. 
As  previously  reported,  A/PR/8/34  influenza  virus- 
infected RMA, but not infected RMA-S,  target cells were 
recognized and lysed by the NP-specific,  H-2Db-restricted 
anti-PR8 CTL line (Table 1). Uninfected control RMA and 
RMA-S target cells were not lysed by these CTL. As expected, 
both tLMA and RMA-S target ceils were sensitized for lysis 
by  these  CTL  in  the  presence  of  exogenous  antigenic 
NP365-380 peptide. 
Similar observations were made with the H-2Kb-restricted 
antigen OVA. After cytoplasmic loading with OVA by the 
osmotic lysis of pinosomes, KMA, but not KMA-S, target 
cells were recognized and lysed by the OVA-specific, H-2K  b- 
restricted CTL clone B3. Unloaded control RMA and RMA-S 
target cells were not lysed by this CTL clone. Both RMA 
and RMA-S target cells were sensitized for lysis by this CTL 
clone in  the  presence of exogenous antigenic  OVA242-ey6 
peptide. 
However, after infection with VSV, both RMA and RMA-S 
target  cells  were  recognized  and  lysed  by  the  H-2K  b- 
restricted, VSV-N-specific CTL line (24). VSV-infected RMA-S 
cells were consistently recognized and lysed by these CTL 
in numerous experiments, with the level of  lysis ranging from 
at least 60% to as high as 100% that of VSV-infected RMA 
cells at the same E/T ratios. Both RMA and RMA-S target 
cells were sensitized for lysis by these CTL in the presence 
of exogenous antigenic VSV-N53-63 peptide. Neither a differ- 
ence in VSV-N expression nor an increase in H-2K  b cell sur- 
face expression by VSV-infected RMA-S targets could explain 
their recognition by CTL.  Both VSV-infected RMA  and 
721  Hosken  and Bevan Table  1.  RMA-S Is Able to Present One Endogenous Class 1-restricted Antigen to Specific CTL 
Percent specific lysis 
APC  Antigen  Peptide  by CTL at E/T of: 
Anti-PR8 CTL line:  10:1  1:1 
R/VIA  -  -  3  2 
RMA  -  NP36s-380  70  48 
RMA  A/PR/8/34  -  49  33 
RMA-S  -  -  0  0 
RMA-S  -  NP36s-380  62  32 
RMA-S  A/PR/8/34  -  2  0 
Anti-OVA B3 CTL clone:  10:1  1:1 
RMA  -  -  0  0 
RMA  -  OVA242-276  77  40 
RMA  OVA  -  44  3O 
RMA-S  -  -  5  2 
RMA-S  -  OVA242-276  78  46 
RMA-S  OVA  -  7  5 
Anti-VSV CTL line:  10:1  1:1 
R/VIA  -  -  0  0 
R]VIA  -  N53qs3  60  37 
RMA  VSV  -  61  41 
RMA-S  -  -  1  0 
RMA-S  -  Ns3-63  86  71 
RMA-S  VSV  -  64  44 
RMA-S cells synthesized quantitatively similar amounts of 
the VSV-N protein as determined by SDS-PAGE (data not 
shown). FACS  |  analysis of VSV-infected RMA-S ceils revealed 
that cell surface expression levels of H-2K  b molecules did not 
increase for up to 6 h  after infection with VSV (data not 
shown). One curious observation was that RMA-S ceils re- 
quired approximately eightfold more VSV virus to become 
targets for CTL recognition than did RMA cells (Fig.  1 A). 
The requirement for a higher MOI in the case of RMA-S 
cannot be explained by the presence of free targeting peptide 
in the viral preparation for a number of reasons.  (a) Up to 
10-fold more virus does not lead to lysis of the human, an- 
tigen presentation-defective cell line T2K  b, which is lysed 
by the CTL in the presence of synthetic VSV-N53-63 peptide 
(Fig.  1 B). A  control human cell line expressing H-2K  b is 
lysed after VSV infection. (b) Fixation of RMA or RMA-S 
cells before incubation with VSV prevents their sensitization 
for lysis by these CTL (data not shown). (c) Brefeldin A treat- 
ment of RMA and RMA-S cells blocks presentation of the 
of the VSV-N epitope after viral infection while allowing pre- 
sentation of exogenous peptide to occur (data not shown). 
Presentation of VSVN by Transfected Cells.  To rule out pos- 
sible nonspecific effects of  VSV infection on RMA-S, we stably 
transfected  RMA  and  RMA-S  cells  with  the  pSV2neo- 
RSV-N plasmid,  which contains both the selectable  G418 
resistance gene and the gene encoding VSV-N (24). Of the 
resulting G418-resistant clones, 4  of 22 RMA  and  1 of 4 
RMA-S clones were recognized and lysed by VSV-N-specific 
CTL (data not shown). A representative experiment (Table 
2) shows that in the absence of exogenous antigenic Ns3-63 
peptide, the transfected clones RMA/N.4 and RMA-S/N.4, 
but not untransfected RMA or RMA-S cells, are recognized 
and lysed by these CTL. Similar to our observations with 
VSV-infected target cells,  RMA-S/N.4  targets were recog- 
nized and lysed by VSV-N-specific  CTL at levels >50%  of 
RMA-N.4 targets at the same E/T ratios.  Sensitization of 
RMA-S/N.4 for CTL recognition was not due to secretion 
of antigenic VSV-N peptides since  supernatants from high 
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Hgure 1.  A higher MOI of VSV 
is  required  for  sensitization  of 
RMA-S for CTL recognition than 
for  gMA.  (A)  gMA  (It)  and 
RMA-S ([7) or (B) T2K  b ([]) and 
Jurkat/K  t' (O) cells were infected 
with VSV at the indicated MOI or 
left uninfected.  In addition,  10 nM 
Ns~3 peptide was added to wells 
containing  uninfected  T2K  b (m) 
and Jurkat/K  b (0) cells during the 
assay.  Points  represent  percent 
specific lysis  of these  cells  by the 
VSV-N-specific CTL line at an E/T 
of 3:1. 
density cultures of these cells did not sensitize RMA or RMA-S 
cells for lysis by CTL (data not shown). Recognition of RMA- 
S/N.4 by CTL could also not be explained by an increase 
in cell surface class I MHC expression  since its expression 
of H-2K b and D b molecules was only slightly higher than 
that of RMA-S cells  when analyzed by FACS  |  (Table 3). 
RMA-S/N. 4 Remains Unable to Present Endogenous Antigens 
to CTL.  To rule out the possibility that the RMA-S/N.4 
transfectant was somehow altered relative to RMA-S in its 
ability to present endogenous antigens, we examined the ability 
of RMA-S/N.4 to present endogenous influenza NP and OVA 
to  specific  CTL.  Upon  infection  with  the  recombinant 
influenza virus X31, both RMA and RMA/N.4 target cells 
Table  2.  VSV-N-specific CTL Recognize RMA-S  Transfected 
with the VSV-N Gene 
Percent  specific 
lysis by anti-VSV 
CTL  at  E/T  of: 
APC  Peptide  10:1  1:1 
RMA  -  0  0 
RJ~A  Ns3~3  72  67 
RMA/N.4  -  70  59 
RMA/N.4  N53-63  59  57 
RMA-S  -  4  1 
R.MA-S  Ns3-63  82  66 
RMA-S/N.4  -  51  36 
RMA-S/N.4  Ns3-~3  63  57 
were recognized and lysed by the NP-specific CTL (Table 4). 
In contrast,  X31-infected RMA-S and RMA-S/N.4  target 
cells were both unable to present endogenous influenza NP 
to these CTL. All target cells were sensitized for lysis by these 
CTL  in  the  presence  of  exogenous  antigenic  NP36s-3s0 
peptide. 
Again,  similar  results  were obtained with  the  H-2K b- 
restricted antigen OVA. OVA-loaded RMA and RMA/N.4, 
but not RMA-S and RMA-S/N.4,  target cells were recog- 
nized and lysed by the OVA-specific CTL (Table 4). Endoge- 
nous expression of the H-2Kb-restricted antigen VSV-N does 
not interfere with presentation  of OVA since OVA-loaded 
RMA/N.4  target cells are recognized by the OVA-specific 
CTL. All cells were sensitized  for lysis by these CTL in the 
presence of exogenous antigenic OVA24v276 peptide.  These 
Table  3.  FACS  |  Analysis of Class I MHC Expression 
by VSV-N Transfectants 
Antibody used to stain cells 
Y3  28.14.8 
APC  None  NFA"  (H-2K  b)  (H-2D  b) 
RMA  5.0'  8.0  208.0  145.0 
RMA/N.4  5.0  8.0  180.0  110.0 
RMA-S  5.0  8.0  17.0  10.0 
RMA-S/N.4  6.0  8.0  21.0  12.0 
* No first antibody. The secondary antibody was FITC-labeled  antibody 
against  mouse immunoglobuIin Fc. 
* Numbers  represent  the  mean  rdative  fluorescence  of  10,000  gated 
events  using a FACScan  |  flow cytometer. 
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Percent  specific lysis 
APC  Antigen  Peptide  by CTL at E/T  of: 
Anti-PR8  CTL line:  10:1  1:1 
RMA  -  -  5  1 
RNIA  -  NP365-3ao  59  35 
R/VIA  X31  -  65  50 
RMA/N.4  -  -  0  0 
RMA/N.4  -  NP36s-380  63  45 
RMA/N.4  X31  -  61  44 
RMA-S  -  -  2  0 
RMA-S  -  NP36s-3s0  66  40 
RMA-S  X31  -  7  5 
RMA-S/N.4  -  -  0  0 
RMA-S/N.4  -  NP36s-3so  39  21 
RMA-S/N.4  X31  -  8  5 
Anti-OVA B3 CTL clone:  10:1  1:1 
R/VIA  -  -  1  3 
R/VIA  -  OVA242-276  55  22 
RMA  OVA  -  37  21 
RMA/N.4  -  -  2  0 
RMA/N.4  -  0VA242-276  55  24 
RMA/N.4  OVA  -  53  26 
RMA-S  -  -  5  2 
RMA-S  -  0VA242-276  78  46 
RMA-S  OVA  -  7  5 
RMA-S/N.4  -  -  5  0 
RMA-S/N.4  -  0VA242-276  43  10 
RMA-S/N.4  OVA  -  0  0 
results  demonstrated  that  the RMA-S/N.4  transfectant  re- 
mained defective in the ability to present endogenous antigens 
to specific CTL and had therefore not reverted to the antigen 
presentation  phenotype  of RMA. 
HPLC Analysis of  Natural VSV-N Peptides Produced by RMA 
and RMA-S.  It  was  theoretically  possible  that  antigenic 
VSV-N peptides were being produced in the cytosol of RMA-S 
but delivered to H-2K  b molecules in some nonphysiological 
manner. If this were the case, it was possible that the natural 
antigenic VSV-N peptides produced by RMA  and RMA-S 
might differ, and that this difference might be detected by 
HPLC analysis. TFA extracts of cell lysates were made from 
both RMA and RMA-S ceUs either untransfected, transfected 
with the VSV-N gene, or infected with VSV. These extracts 
were chromatographed  on a  C18  HPLC column  and  frac- 
tions tested for the presence of antigenic VSV-N peptides by 
their ability to sensitize RMA-S target cells cultured at 31~ 
overnight (RMA-S [31~  for recognition by VSV-N-specific 
CTL.  Neither extracts from ILMA nor RMA-S cells senti- 
tized the RMA-S (31~  targets for lysis by the VSV-N-specific 
CTL  (Fig.  2).  Extracts from both RMA  and ILMA-S cells 
either transfected with the VSV-N gene or infected with VSV 
all sensitized RMA-S (31~  targets for lysis by these CTL. 
The  sensitizing  activity from each of these extracts eluted 
from the HPLC column primarily in fraction 30,  thus,  the 
natural antigenic VSV-N peptides contained in these extracts 
are essentially indistinguishable by HPLC. The synthetic pep- 
tide Ns2-sg, which corresponds to the natural antigenic VSV-N 
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Figure 2.  HPLC  analysis of the natural VSV-N peptidcs in KMA and 1LMA-S extracts. TFA extracts were prepared from cells either untreated (KMA, 
RMA-S), transfected with the VSV-N gene (RMA/N.4, ILMA-S/N.4),  or infected with VSV at an MOI of 40 (ILMA/VSV, tLMA-S/VSV). These 
extracts were chromatographed by reverse-phase  HPI.C and the collected fractions tested for their ability to sensitize KMA-S cells grown at 310C for 
lysis by the VSV-N specific CTL line at an E/T ratio of 3:1. 
peptide produced by VSV infected cells (27), also duted from 
this HPLC column in fraction 30 under the conditions used 
in this experiment (data not shown). 
Mapping the Defect in RMA-S by Cell Fusion.  We next asked 
if the tLMA-S phenotype could be attributed  to a defect on 
chromosome 17, which encodes the murine MHC. We first 
fused R_MA-S (H-2 b, BzM  b, Thy-l.2) to the nonmutant cell 
line BW Lyt-2.4  (H-2  k, BzM ...... b, Thy-l.1) and isolated in- 
dividual fusion dones for analysis. One of these clones, ILxB.6, 
was subsequently subjected to selection by an alloreactive anti- 
H-2 k CTL line for loss of the BW Lyt-2.4-derived  chromo- 
some 17. The resulting cell populations Sd 3, Sd 4, and Sd 
5 were each products of a single round of CTL selection in 
individual cultures. The ILxB.6 fusion clone and the selected 
cell populations were then analyzed  for cell  surface class I 
MHC expression  phenotype, for the ability to present en- 
dogenous influenza NP to specific CTL, and for presence of 
the BW Lyt-2.4-derived chromosome 17. Consistent with 
the results of a previously reported fusion of RdClA-S with 
a nonmutant fibroblast cell line (14), fusion of RMA-S with 
BW Lyt-2.4 resulted in elevated expression  of H-2  b class I 
MHC molecules and ~zm  b at the cell surface relative to the 
levels expressed by RMA-S (Table 5). This observation  is in- 
terpreted to mean that the low level of class I MHC cell sur- 
face expression by RMA-S is not caused by defects in either 
the class I heavy chains or/~2m.  The KxB.6 clone also ex- 
Table  5.  Sel 3,  4, and 5 l~p~y  ~e RMA-S C~  I MHC Surface ExpressDn Phenotype 
Antibody used to stain cells 
AF6-88.5.3  B22.049  AF3-12.1.3  15.5.5S  $19.8  19E12  FITC-30H12 
Exp.  APC  None  NFA*  (H-2K  b)  (H-2D h)  (H-2K  k)  (H-2D k)  (B2M  8)  (Thy-l.1)  (Thy-l.2) 
1  ILMA  3*  15  309  175  22  19  298  19  104 
RMA-S  3  20  45  28  24  23  44  21  126 
BW  Lyt-2.4  2  19  19  22  232  65  25  535  9 
KxB.6  3  13  171  90  141  64  201  1,583  90 
Sd 3  3  20  38  21  18  19  16  989  57 
2  RMA  3  5  154  91  6  6  111  5  72 
R2VIA-S  3  5  13  7  6  5  8  6  72 
BWLyt-2.4  2  5  6  6  136  34  6  361  4 
R.xB.6  3  5  48  38  77  22  50  617  51 
Sel 4  3  5  10  7  5  5  6  500  41 
Sel  5  3  4  13  5  5  5  6  369  34 
* No first antibody. The secondary antibody was FITC-labeled antibody against mouse immunoglobulin  Ft. 
* Numbers  represent the mean relative fluorescence of 10,000  gated events using a FACScan  |  flow cytometer. 
725  Hosken and Bevan Table  6.  Sel 3,  4,  and 5 are Defective for Presentation of 
Endogenous Influenza  NP to Specific CTL 
Percent specific 
lysis by anti-PR8 
CTL  at  E/T  of: 
APC  Antigen  Peptide  10:1  1:1 
RMA  -  -  0  0 
RMA  -  NP36s-3s0  72  20 
R/vIA  X31  -  58  23 
RMA-S  -  -  2  3 
RMA-S  -  NP36s-3s0  43  13 
RMA-S  X31  -  1  0 
BW  Lyt  2.4  -  -  22  3 
BW  Lyt  2.4  -  NP36s-ss0  30  4 
BW  Lyt  2.4  X31  -  28  9 
RxB.6  -  -  2  2 
RxB.6  -  NP3~s-3s0  59  23 
RxS.6  X31  -  45  16 
Sel  3  -  -  18  0 
Sel  3  -  NP365-3s0  55  28 
Sel  3  X31  -  21  4 
Sel  4  -  -  10  0 
Sel  4  -  NP36s-3so  48  12 
Sel  4  X31  -  14  1 
Sel  5  -  -  9  1 
Sel  5  -  NP365-3so  65  19 
Sel  5  X31  -  15  3 
pressed the BW  Lyt-2.4-derived  H-2  k class I  MHC  and 
Thy-l.1 molecules at its cell surface, indicating that it was 
the product of a fusion event between RMA-S and BW Lyt- 
2.4. Also consistent with previous fusion experiments per- 
formed with RMA-S (14) was the observation that RxB.6 
was capable of presenting endogenous influenza NP, as well 
as  exogenous  antigenic  NP365-380 peptide,  to  NP-specific 
CTL (Table 6). 
The CTL-selected cell populations  Sel 3, 4, and 5 pheno- 
typically resembled RMA-S in being homogeneous for low 
cell surface levels of H-2  b class I MHC molecules and defec- 
tive in the ability to present endogenous influenza NP to NP- 
specific CTL (Tables 5 and 6). Sel 3, 4, and 5 were sensitized 
for specific  CTL lysis in the presence of exogenous antigenic 
NP36s-3s0 peptide, indicating that they had not been selected 
for resistance to lysis by CTL. However, unlike RMA-S, they 
were positive for cell surface  expression  of BW Lyt-2.4-derived 
Thy-l.1 molecules (Table 5), indicating that they were de- 
rived from the tLxB.6 fusion clone and not from residual 
RMA-S cells in the cultures. Sd 3, 4, and 5 appeared to have 
lost the BW Lyt-2.4 chromosome 17 since they were nega- 
tive for H-2  k expression by FACS  |  analysis (Table 5). Loss 
of the BW Lyt-2.4-derived chromosome 17 by these popula- 
tions was confirmed  by Southern blot analysis using a probe 
spanning the genomic H-2K  b promoter. This probe hybrid- 
ized to two polymorphic bands in DNA from each of the 
control H-2  k haplotype  cells tested,  one of which is dis- 
tinctly different from the four polymorphic bands detected 
in DNA from control H-2  b haplotype cells (Fig. 3). R.xB.6 
DNA contains both the H-2  b- and H-2k-derived bands, in- 
dicating that it contains both the RMA-S and BW Lyt-2.4- 
derived chromosomes 17. DNA from each of the selected 
cell populations contains only the H-2b-derived polymorphic 
bands, confirming that each of these populations  have lost 
the BW Lyt-2.4-derived chromosome 17. Thus in three of 
three independent cases, we observed that loss of the BW 
Lyt-2.4-derived  chromosome 17 by RxB.6 was associated  with 
reversion to the RMA-S phenotype. These data imply that 
the defect responsible for the RMA-S phenotype is likely to 
reside on chromosome 17. 
Discussion 
The murine RMA-S and human LCL 721.174 mutant cell 
lines display similar defective phenotypes. Both of these cell 
lines retain the majority of their class I MHC molecules in 
the ER and both are defective in the ability to present en- 
dogenous dass I MHC-restricted antigens to CTL (5, 9, 12, 
13). The LCL 721.174 phenotype has been attributed to the 
ddetion of genes encoded within the class II region of the 
MHC on human chromosome 6 (9, 10, 15). Included within 
this deletion is Y3, a putative peptide transporter gene, which 
has been shown to restore high levels of cell surface class I 
MHC expression by a second human mutant cell line, LCL 
721.134, lacking Y3 expression (18). The Y3 gene does not 
restore high levels of cell surface class I expression by LCL 
721.174, indicating that expression of other genes encoded 
within the deleted region of the MHC in these cells may 
also be necessary to correct the LCL 721.174 defect (18). 
The RMA-S cell line has been observed to express mRNA 
for, and thus has not deleted, its MHC-encoded putative pep- 
tide transporter genes HAM-1 and -2 (20). Our data demon- 
strate that the RMA-S phenotype can be attributed to a de- 
fect that maps to the murine chromosome 17, which encodes 
the MHC. Fusion of RMA-S with BW Lyt-2.4 resulted in 
restoration of the wild-type RMA phenotype. This was also 
true when RMA-S was fused with a nonmutant fibroblast 
cell line (14). Thus, the RMA-S phenotype, like that of LCL 
721.174,  is  recessive rather than  dominant in  cell fusion 
experiments.  Loss of  the  BW-derived  chromosome  17 
resulted in reversion  of the RxB.6 hybrid to the RMA-S pheno- 
type in three of three independent selected ceU populations. 
Taken together with the observation that LCL 721.174 and 
RMA-S display similar phenotypes, our data, which map the 
RMA-S defect to chromosome 17, suggest that the defect 
in RMA-S is likely to reside within the MHC. 
The defect in RMA-S and LCL 721.174 results in the ina- 
726  RMA-S Can Present an Endogenous Antigen Figure 3.  The CTL-selected populations Sel 3, 4, and 
5  have lost  the BW  Lyt-2.4-derived chromosome  17. 
Genomic DNA from the indicated spleen or tumor cells 
was subjected to Southern blot analysis. Each lane con- 
rains 2/zg of HindIll-digested genomic DNA. The blot 
was probed with a purified 3-kb EcoKI-HindlII  fragment 
spanning the genomic H-2Kb promoter. 
bility of these cell lines to present several endogenous class 
I-restricted antigens (5, 9, 12, 13). However, we have found 
that they differ significantly in their ability to present at least 
one endogenous antigen, VSV-N. We have previously reported 
that LCL 721.174 cells expressing H-2K  b (T2K  b) were un- 
able to present endogenous VSV-N  to VSV-N-specific  CTL 
(13). Even a very high MO1 with VSV does not lead to the 
appearance  of the  H-2Kb-restricted  CTL  determinant  on 
T2K  b cells (Fig.  1 B). The inability of T2K  b cells to present 
VSV-N was not due to a failure to infect these cells with VSV 
since VSV-N  expression by VSV-infected T2K  b cells can be 
detected by SDS-PAGE  (data not shown).  We have shown 
here that RMA-S was able to present endogenous VSV-N 
to specific CTL. This was true whether RMA-S was infected 
with VSV or transfected with the VSV-N gene, indicating 
that presentation of  VSV-N was not due to nonspecific effects 
of  viral infection. CTL recognition of  RMA-S cells expressing 
VSV-N was generally less efficient than recognition of RMA 
cells expressing VSV-N, although specific lysis of RMA-S cells 
was always ~>50-60"/o that of RMA cells. This was not due 
to differences in expression of  VSV-N since both infected and 
transfected RMA-S cells expressed equal or greater amounts 
of VSV-N  compared with similarly treated RMA cells,  as 
determined by SDS-PAGE  (data not shown). 
There are several possible  explanations for the ability of 
RMA-S, but not T2K  b,  to present endogenous VSV-N  to 
specific CTL. First, it is possible that the endogenous VSV-N 
peptide is delivered to H-2K  b molecules in RMA-S in some 
nonphysiological manner. It is possible that the VSV-N pro- 
tein has access to and is degraded in the ER in RMA-S, but 
this is unlikely given that VSV-N lacks a signal sequence and 
has been observed to be localized in the cytosol of  mammalian 
cells either infected with VSV or transfected with the VSV-N 
gene (28, 29).  It is also possible that other nonphysiological 
transport mechanisms, such as the signal sequence-mediated 
transport mechanism, could deliver the VSV-N  peptide to 
H-2K  b molecules in RMA-S.  We feel that this explanation 
is unlikely in that these mechanisms would have to operate 
only in RMA-S and not in T2K  b cells. Furthermore, if the 
VSV-N peptide were being loaded onto H-2K  b molecules by 
some nonphysiological pathway in R/VIA-S, one might ex- 
pect to find that the peptide might differ from the natural 
octamer expressed by wild-type cells. In fact, we found that 
the peptides in  extracts from R/VIA and RMA-S cells ex- 
pressing VSV-N  were indistinguishable by HPLC. 
We favor a second possible explanation:  that the system 
that transports antigenic peptides from the cytosol to the ER 
in wild-type cells may still be present in RMA-S and retain 
partial function. This explanation would be consistent with 
the idea that the RMA-S phenotype is due to a point muta- 
tion rather than a genomic deletion like that observed in LCL 
721.174 (30).  It would also be consistent with the observa- 
tion that HAM-1 and -2 mRNA expression can be detected 
in RMA-S (20).  A  partially defective system, if present in 
RMA-S, might inefficiently transport all cytosolic antigenic 
peptides produced. If this were the case, then lack of  RMA-S 
recognition by CTL might be explained by differences in an- 
tigen density requirements for recognition and lysis of these 
targets by different antigen-specific CTL (12). Alternatively, 
this crippled system might transport only a subset of the cyto- 
solic antigenic peptides produced by RMA-S. In either case, 
this explanation would predict that the class I molecules ex- 
pressed stably by RMA-S at the cell surface are not empty, 
but are occupied by a subset  of self peptides. 
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